-
Mashup Score: 0Rheumatology: Believe It or Not (4/25/2025) | RheumNow - 16 minute(s) ago
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?
Source: rheumnow.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Frontiers | Profiling the expression and functional roles of mRNAs and lncRNAs associated with post-stroke aphasia - 16 minute(s) ago
1 Department of Rehabilitation Medicine, Shanghai Pudong New Area Guangming Hospital of Traditional Chinese Medicine, Shanghai, China 2 School of Foreign Languages, Shanghai Jiao Tong University, Shanghai, China Objective: Post-stroke aphasia (PSA) is one of the primary causes of post-stroke impairment, although its underlying mechanism is unknown; therefore, this study aimed to identify the long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) linked to PSA and to understand the potential processes
Source: www.frontiersin.orgCategories: General Medicine News, NeurologyTweet-
New Research: Profiling the expression and functional roles of mRNAs and lncRNAs associated with post-stroke aphasia https://t.co/XjDUWiz3Gj #FrontiersIn #MolecularNeuroscience
-
-
Mashup Score: 0Increased Operative Time yet Enhanced Accuracy in Computer-Assisted vs. Mechanical Hip Resurfacing Arthroplasty: An Updated Systematic Review and Meta-Analysis - 16 minute(s) ago
Hip resurfacing arthroplasty (HRA) is considered a highly complex procedure, requiring advanced specialization and training beyond that of conventional total hip arthroplasty (THA). With the advent of computer-assisted navigation in…
Source: www.jbjs.orgCategories: General Medicine News, RheumatologyTweet-
"Increased Operative Time yet Enhanced Accuracy in Computer-Assisted vs. Mechanical Hip Resurfacing Arthroplasty: An Updated Systematic Review and Meta-Analysis" Shanaa et al. Read online at https://t.co/OSJXX8JtS8 https://t.co/bGWzFczQ5H
-
-
Mashup Score: 0Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD - 16 minute(s) ago
Dr Lamanna discusses how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in CLL.
Source: www.onclive.comCategories: General Medicine NewsTweet-
In yesterday's episode of #OncLiveonAir🎙️, Nicole Lamana, MD, of @columbiacancer, discusses how disease progression, treatment intolerance, and prior therapy exposure inform the choice to initiate pirtobrutinib in CLL. Listen to the full episode 🎧: https://t.co/7V67PBhy9M https://t.co/sIP9K5hqgm
-
-
Mashup Score: 0More drugmakers plan US manufacturing investment: 5 things to know - Becker's Hospital Review | Healthcare News & Analysis - 16 minute(s) ago
A growing number of pharmaceutical companies are sharing plans to ramp up domestic manufacturing capacity amid recent tariffs imposed by the Trump administration. Here are five things to know:
Source: www.beckershospitalreview.comCategories: General Medicine NewsTweet-
More drugmakers plan #US #manufacturing investment: 5 things to know | #pharma #Trump #tarrifs https://t.co/ekzlXvVF4t
-
-
Mashup Score: 1AACR Annual Meeting - 16 minute(s) ago
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
#OncLive will be on site at the 2024 AACR Annual Meeting! If you want to discuss your research with our team, stop by to speak with us this weekend, or email chryan@onclive.com for more information. See you in San Diego! @AACR #AACR24 ✈️ https://t.co/3nJiUIxX6x https://t.co/DGYQIL1DF3
-
-
Mashup Score: 185 reasons why the COVID-19 vaccine needs clinical trials before approval - 27 minute(s) ago
I couldn’t help but notice that the mainstream media is upset that going forward the fall COVID 19 booster might require randomized trials measuring clinical endpoints, rather than allowing Peter Marks to pick a variant target (based on an analogy to him buying milk) and then generate antibodies against the target.
Source: www.drvinayprasad.comCategories: General Medicine NewsTweet-
https://t.co/XJMvStPfxK
-
-
Mashup Score: 1Welcome! You are invited to join a meeting: CSO x SONIA - Live Event. After registering, you will receive a confirmation email about joining the meeting. - 30 minute(s) ago
Welcome! You are invited to join a meeting: CSO x SONIA – Live Event. After registering, you will receive a confirmation email about joining the meeting.
Source: queensu.zoom.usCategories: General Medicine NewsTweet-
RT @csoncol: Link to register- https://t.co/iLq7sd9ruJ
-
-
Mashup Score: 0An intranasally administered IgM protects against antigenically distinct subtypes of influenza A viruses - 31 minute(s) ago
Nature Communications – Influenza A HA plasticity often leads to resistant strains that compromise mAb potency as bivalent IgGs. Here, the authors show that engineered IgM molecules overcome this…
Source: www.nature.comCategories: General Medicine News, Infectious DiseaseTweet-
Collaborators constructed 18 IgM antibodies from known broadly neutralizing IgGs targeting different influenza A virus (IAV) hemagglutinin epitopes and evaluated their breadth and potency of neutralization against distinct H1N1 and H3N2 IAVs. 🦠 https://t.co/DLg1jO2GQ0 https://t.co/D81ErtjYaz
-
-
Mashup Score: 0Novo Nordisk Forms GLP-1 Partnership with Hims & Hers - MedCity News - 39 minute(s) ago
Hims & Hers is now offering discounted access to Wegovy, a GLP-1 manufactured by Novo Nordisk, on its platform.
Source: medcitynews.comCategories: General Medicine NewsTweet-
Novo Nordisk Forms GLP-1 Partnership with Hims & Hers https://t.co/VWdWdjdbqr
-
Rheumatology: Believe It or Not (4/25/2025) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. Should we believe the reviews and metanalyses? https://t.co/pJFhcBkvjO https://t.co/9evGknrMSo